PubMed=8132740; DOI=10.1172/JCI117048; PMCID=PMC294021
Markowitz S.D., Myeroff L.L., Cooper M.J., Traicoff J.L., Kochera M.E., Lutterbaugh J.D., Swiriduk M., Willson J.K.V.
A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene.
J. Clin. Invest. 93:1005-1013(1994)

PubMed=7761852; DOI=10.1126/science.7761852
Markowitz S.D., Wang J., Myeroff L.L., Parsons R., Sun L.-Z., Lutterbaugh J.D., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B., Brattain M.G., Willson J.K.V.
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.
Science 268:1336-1338(1995)

PubMed=12595761; DOI=10.1007/BF02256060
Traicoff J.L., Periyasamy S., Brattain M.G., Grady W.M., Casey G.
Reconstitution of TGF-beta sensitivity in the VACO-411 human colon carcinoma line by somatic cell fusion with MCF-7.
J. Biomed. Sci. 10:253-259(2003)

PubMed=25926053; DOI=10.1038/ncomms8002
Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Nat. Commun. 6:7002.1-7002.10(2015)